Literature DB >> 20431542

Production of mice using iPS cells and tetraploid complementation.

Xiao-Yang Zhao1, Zhuo Lv, Wei Li, Fanyi Zeng, Qi Zhou.   

Abstract

Induced pluripotent stem cells (iPSCs) are considered to be an attractive alternative to embryonic stem cells (ESCs) and may provide great potential for clinical applications in regenerative medicine. Although possessing characteristics similar to ESCs, the true pluripotency of these newly studied iPSCs was not known because none of the previously developed iPSCs passed the tetraploid complementation assay, which is regarded as the most stringent test for pluripotency. We have recently shown that by modifying some of the culture conditions for inducing iPSCs, we were able to generate cell lines of high pluripotency, resulting in the production of live-born, fertile animals through tetraploid complementation. In this paper, we describe details of our methods of generating iPS cell lines and subsequently producing full-term live animals through the tetraploid complementation assay; the procedure can be completed within 2 months.

Entities:  

Mesh:

Year:  2010        PMID: 20431542     DOI: 10.1038/nprot.2010.61

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  17 in total

1.  Production of chimeras by aggregation of embryonic stem cells with diploid or tetraploid mouse embryos.

Authors:  Guy S Eakin; Anna-Katerina Hadjantonakis
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 2.  Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming.

Authors:  Rudolf Jaenisch; Richard Young
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

3.  iPS cells can support full-term development of tetraploid blastocyst-complemented embryos.

Authors:  Lan Kang; Jianle Wang; Yu Zhang; Zhaohui Kou; Shaorong Gao
Journal:  Cell Stem Cell       Date:  2009-07-23       Impact factor: 24.633

4.  Germline-specific expression of the Oct-4/green fluorescent protein (GFP) transgene in mice.

Authors:  T Yoshimizu; N Sugiyama; M De Felice; Y I Yeom; K Ohbo; K Masuko; M Obinata; K Abe; H R Schöler; Y Matsui
Journal:  Dev Growth Differ       Date:  1999-12       Impact factor: 2.053

5.  Generation of completely embryonic stem cell-derived mutant mice using tetraploid blastocyst injection.

Authors:  Z Q Wang; F Kiefer; P Urbánek; E F Wagner
Journal:  Mech Dev       Date:  1997-03       Impact factor: 1.882

6.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

Review 7.  Technical challenges in using human induced pluripotent stem cells to model disease.

Authors:  Krishanu Saha; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

8.  Induction of pluripotent stem cells from fibroblast cultures.

Authors:  Kazutoshi Takahashi; Keisuke Okita; Masato Nakagawa; Shinya Yamanaka
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

9.  iPS cells produce viable mice through tetraploid complementation.

Authors:  Xiao-yang Zhao; Wei Li; Zhuo Lv; Lei Liu; Man Tong; Tang Hai; Jie Hao; Chang-long Guo; Qing-wen Ma; Liu Wang; Fanyi Zeng; Qi Zhou
Journal:  Nature       Date:  2009-09-03       Impact factor: 49.962

10.  Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.

Authors:  A Nagy; J Rossant; R Nagy; W Abramow-Newerly; J C Roder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

View more
  20 in total

1.  Rapid conversion of human ESCs into mouse ESC-like pluripotent state by optimizing culture conditions.

Authors:  Qi Gu; Jie Hao; Xiao-yang Zhao; Wei Li; Lei Liu; Liu Wang; Zhong-hua Liu; Qi Zhou
Journal:  Protein Cell       Date:  2012-01-21       Impact factor: 14.870

2.  Some Ethical Concerns About Human Induced Pluripotent Stem Cells.

Authors:  Yue Liang Zheng
Journal:  Sci Eng Ethics       Date:  2015-08-15       Impact factor: 3.525

3.  iPS cells generated without c-Myc have active Dlk1-Dio3 region and are capable of producing full-term mice through tetraploid complementation.

Authors:  Wei Li; Xiao-Yang Zhao; Hai-Feng Wan; Ying Zhang; Lei Liu; Zhuo Lv; Xiu-Jie Wang; Liu Wang; Qi Zhou
Journal:  Cell Res       Date:  2011-02-15       Impact factor: 25.617

4.  A single-cell identification and capture chip for automatically and rapidly determining hydraulic permeability of cells.

Authors:  Yeye Xu; Weiping Ding; Shibo Li; Chengpan Li; Dayong Gao; Bensheng Qiu
Journal:  Anal Bioanal Chem       Date:  2020-05-21       Impact factor: 4.142

5.  Tetraploid complementation proves pluripotency of induced pluripotent stem cells derived from adipose tissue.

Authors:  C Zhou; X Cai; Y Fu; X Wei; N Fu; J Xie; Y Lin
Journal:  Cell Prolif       Date:  2014-11-28       Impact factor: 6.831

Review 6.  Application of Induced Pluripotent Stem Cells in Liver Diseases.

Authors:  Yue Yu; Xuehao Wang; Scott L Nyberg
Journal:  Cell Med       Date:  2014-04-22

7.  A combined epigenetic and non-genetic approach for reprogramming human somatic cells.

Authors:  Jinnuo Han; Perminder S Sachdev; Kuldip S Sidhu
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 8.  Mechanisms and models of somatic cell reprogramming.

Authors:  Yosef Buganim; Dina A Faddah; Rudolf Jaenisch
Journal:  Nat Rev Genet       Date:  2013-06       Impact factor: 53.242

Review 9.  Accelerating cancer modeling with RNAi and nongermline genetically engineered mouse models.

Authors:  Geulah Livshits; Scott W Lowe
Journal:  Cold Spring Harb Protoc       Date:  2013-11-01

10.  A pipeline for the generation of shRNA transgenic mice.

Authors:  Lukas E Dow; Prem K Premsrirut; Johannes Zuber; Christof Fellmann; Katherine McJunkin; Cornelius Miething; Youngkyu Park; Ross A Dickins; Gregory J Hannon; Scott W Lowe
Journal:  Nat Protoc       Date:  2012-02-02       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.